Endologix Inc (ELGX) 12.43 $ELGX
Endologix Shares Down 10.5% Since SmarTrend's Sell Call (ELGX)
Comtex SmarTrend(R) - Wed Apr 16, 9:27AM CDT
SmarTrend identified a Downtrend for Endologix (NASDAQ:ELGX) on February 28th, 2014 at $13.41. In approximately 2 months, Endologix has returned 10.48% as of today's recent price of $12.00.
Health Care Sector Equities Update -- Research on Endologix, Align Technology, Spectranetics, and Unilife
PR Newswire - Mon Apr 14, 8:00AM CDT
The trading session on Friday, April 11, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,026.75, down 0.89% and the NASDAQ Composite closed at 3,999.73, down 1.34%. The S&P 500 finished the session 0.95% lower at 1,815.69. The losses were broad based as all the ten sectors posted losses. The S&P 500 Health Care Sector Index finished the day at 644.74, down 1.07%, and the same has declined 2.36% in last three months. Investor-Edge has initiated coverage on the following equities: Endologix Inc. (NASDAQ: ELGX), Align Technology Inc. (NASDAQ: ALGN), Spectranetics Corp. (NASDAQ: SPNC) and Unilife Corp. (NASDAQ: UNIS). Free technical research on ELGX, ALGN, SPNC and UNIS can be downloaded upon signing up at:
Bear of the Day: Endologix (ELGX) - Bear of the Day
Neena Mishra - ZACKS - Wed Mar 26, 2:31AM CDT
Bear of the Day: Endologix (ELGX) - Bear of the Day
Upgrade Alert for Endologix (ELGX)
Comtex SmarTrend(R) - Fri Mar 21, 8:00AM CDT
Endologix (NASDAQ:ELGX) was upgraded from Neutral to Buy at BTIG today. The stock closed yesterday at $12.96 on volume of 974,000 shares, below average daily volume of 995,000. Endologix, Inc. develops, manufactures, sells, and markets minimally invasive treatments for vascular diseases. The Company's products include the Powerlink System, a catheter-based endoluminal stent graft that treats abdominal aortic aneurysms. Endologix's products are sold in the United States as well as international markets.
Moving Average Crossover: Great News for Endologix (ELGX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:47AM CDT
Moving Average Crossover: Great News for Endologix (ELGX)?
Why Endologix (ELGX) Could Be Positioned for a Slump - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 7:43AM CDT
It may be a good decision to sell Endologix as its price dropped significantly in the past four weeks, the stock witnessed a negative trend in earnings estimate revisions and a poor Zacks Rank confirms weakness.
Endologix to Participate in Two Investor Conferences in March
GlobeNewswire - Fri Mar 07, 2:59AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chairman and Chief Executive Officer, and Shelley Thunen, Chief Financial Officer, are scheduled to participate at two investor conferences in March. The first conference is the 26th Annual ROTH Conference in Dana Point, CA.
Nasdaq stocks posting largest volume increases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Why Endologix Inc. Shares Were Clobbered
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 12:53PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Endologix , a developer of medical devices...
Will This Downgrade Hurt Endologix (ELGX) Today?
at The Street - Fri Feb 28, 8:45AM CST
Oppenheimer downgraded Endologix (ELGX) to "perform" from "outperform" and set a $16 target price. The firm noted domestic business is facing increased competition.
Downgrade Alert for Endologix (ELGX)
Comtex SmarTrend(R) - Fri Feb 28, 7:06AM CST
Endologix (NASDAQ:ELGX) was downgraded from Outperform to Perform at Oppenheimer today. The stock closed yesterday at $17.87 on volume of 596,000 shares, above average daily volume of 398,000. Endologix, Inc. develops, manufactures, sells, and markets minimally invasive treatments for vascular diseases. The Company's products include the Powerlink System, a catheter-based endoluminal stent graft that treats abdominal aortic aneurysms. Endologix's products are sold in the United States as well as international markets.
Endologix Reports 25% and 21% Revenue Growth for the Full Year and Fourth Quarter 2013
GlobeNewswire - Thu Feb 27, 3:14PM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and twelve months ended December 31, 2013.
Endologix Announces US Launch of the VELA(TM) Proximal Endograft System
GlobeNewswire - Mon Feb 10, 8:39AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the United States launch of its new VELA(TM) Proximal Endograft System. The VELA Proximal Endograft is specifically designed for the treatment of proximal aortic neck anatomies during an endovascular aneurysm repair ('EVAR'
procedure using the Endologix AFX Endovascular AAA System. The proximal neck is the portion of the aorta that is above the aneurysm and below the renal arteries.
Endologix to Report Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014
GlobeNewswire - Thu Feb 06, 3:15PM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2013 financial results, which will take place on Thursday, February 27, 2014 after the close of the market.
Endologix Announces Enrollment of First Patient in EVAS FORWARD-IDE Clinical Trial
GlobeNewswire - Tue Jan 21, 8:00AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the first patient was treated in the EVAS FORWARD-IDE clinical trial, the Company's pivotal clinical trial to evaluate the safety and effectiveness of the Nellix(R) EndoVascular Aneurysm Sealing System ("Nellix EVAS System" for the endovascular repair of infrarenal abdominal aortic aneurysms. The EVAS FORWARD-IDE clinical trial is approved to enroll 180 patients at up to 30 centers in the U.S., Canada and Europe, of which approximately 25 will be in the U.S. The first procedure was performed by Professor Dittmar Boeckler, MD, a vascular surgeon at Heidelberg University Hospital in Germany.
Healthcare Conference Schedules and Additional Loans - Research Report on Clovis Oncology, LifePoint, Halozyme, Infinity, and Endologix
PR Newswire - Thu Jan 09, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Clovis Oncology, Inc. (NASDAQ: CLVS), LifePoint Hospitals, Inc. (NASDAQ: LPNT), Halozyme Therapeutics, Inc. (NASDAQ: HALO), Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), and Endologix, Inc. (NASDAQ: ELGX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Endologix to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Jan 06, 8:00AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 32 Annual JP Morgan Healthcare Conference in San Francisco, CA.
Endologix Shares Down 10.5% Since SmarTrend's Sell Call (ELGX)
Comtex SmarTrend(R) - Wed Apr 16, 9:27AM CDT
SmarTrend identified a Downtrend for Endologix (NASDAQ:ELGX) on February 28th, 2014 at $13.41. In approximately 2 months, Endologix has returned 10.48% as of today's recent price of $12.00.
Health Care Sector Equities Update -- Research on Endologix, Align Technology, Spectranetics, and Unilife
PR Newswire - Mon Apr 14, 8:00AM CDT
The trading session on Friday, April 11, 2014 ended on a lower note as the Dow Jones Industrial Average finished at 16,026.75, down 0.89% and the NASDAQ Composite closed at 3,999.73, down 1.34%. The S&P 500 finished the session 0.95% lower at 1,815.69. The losses were broad based as all the ten sectors posted losses. The S&P 500 Health Care Sector Index finished the day at 644.74, down 1.07%, and the same has declined 2.36% in last three months. Investor-Edge has initiated coverage on the following equities: Endologix Inc. (NASDAQ: ELGX), Align Technology Inc. (NASDAQ: ALGN), Spectranetics Corp. (NASDAQ: SPNC) and Unilife Corp. (NASDAQ: UNIS). Free technical research on ELGX, ALGN, SPNC and UNIS can be downloaded upon signing up at:
Bear of the Day: Endologix (ELGX) - Bear of the Day
Neena Mishra - ZACKS - Wed Mar 26, 2:31AM CDT
Bear of the Day: Endologix (ELGX) - Bear of the Day
Upgrade Alert for Endologix (ELGX)
Comtex SmarTrend(R) - Fri Mar 21, 8:00AM CDT
Endologix (NASDAQ:ELGX) was upgraded from Neutral to Buy at BTIG today. The stock closed yesterday at $12.96 on volume of 974,000 shares, below average daily volume of 995,000. Endologix, Inc. develops, manufactures, sells, and markets minimally invasive treatments for vascular diseases. The Company's products include the Powerlink System, a catheter-based endoluminal stent graft that treats abdominal aortic aneurysms. Endologix's products are sold in the United States as well as international markets.
Moving Average Crossover: Great News for Endologix (ELGX)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:47AM CDT
Moving Average Crossover: Great News for Endologix (ELGX)?
Why Endologix (ELGX) Could Be Positioned for a Slump - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 13, 7:43AM CDT
It may be a good decision to sell Endologix as its price dropped significantly in the past four weeks, the stock witnessed a negative trend in earnings estimate revisions and a poor Zacks Rank confirms weakness.
Endologix to Participate in Two Investor Conferences in March
GlobeNewswire - Fri Mar 07, 2:59AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, Chairman and Chief Executive Officer, and Shelley Thunen, Chief Financial Officer, are scheduled to participate at two investor conferences in March. The first conference is the 26th Annual ROTH Conference in Dana Point, CA.
Nasdaq stocks posting largest volume increases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
Nasdaq stocks posting largest percentage decreases
AP - Fri Feb 28, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Why Endologix Inc. Shares Were Clobbered
Sean Williams, The Motley Fool - Motley Fool - Fri Feb 28, 12:53PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of Endologix , a developer of medical devices...
Will This Downgrade Hurt Endologix (ELGX) Today?
at The Street - Fri Feb 28, 8:45AM CST
Oppenheimer downgraded Endologix (ELGX) to "perform" from "outperform" and set a $16 target price. The firm noted domestic business is facing increased competition.
Downgrade Alert for Endologix (ELGX)
Comtex SmarTrend(R) - Fri Feb 28, 7:06AM CST
Endologix (NASDAQ:ELGX) was downgraded from Outperform to Perform at Oppenheimer today. The stock closed yesterday at $17.87 on volume of 596,000 shares, above average daily volume of 398,000. Endologix, Inc. develops, manufactures, sells, and markets minimally invasive treatments for vascular diseases. The Company's products include the Powerlink System, a catheter-based endoluminal stent graft that treats abdominal aortic aneurysms. Endologix's products are sold in the United States as well as international markets.
Endologix Reports 25% and 21% Revenue Growth for the Full Year and Fourth Quarter 2013
GlobeNewswire - Thu Feb 27, 3:14PM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, today announced financial results for the three and twelve months ended December 31, 2013.
Endologix Announces US Launch of the VELA(TM) Proximal Endograft System
GlobeNewswire - Mon Feb 10, 8:39AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today the United States launch of its new VELA(TM) Proximal Endograft System. The VELA Proximal Endograft is specifically designed for the treatment of proximal aortic neck anatomies during an endovascular aneurysm repair ('EVAR'
procedure using the Endologix AFX Endovascular AAA System. The proximal neck is the portion of the aorta that is above the aneurysm and below the renal arteries. Endologix to Report Fourth Quarter and Full Year 2013 Financial Results on February 27, 2014
GlobeNewswire - Thu Feb 06, 3:15PM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today details relating to the release of its fourth quarter and full year 2013 financial results, which will take place on Thursday, February 27, 2014 after the close of the market.
Endologix Announces Enrollment of First Patient in EVAS FORWARD-IDE Clinical Trial
GlobeNewswire - Tue Jan 21, 8:00AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that the first patient was treated in the EVAS FORWARD-IDE clinical trial, the Company's pivotal clinical trial to evaluate the safety and effectiveness of the Nellix(R) EndoVascular Aneurysm Sealing System ("Nellix EVAS System"
for the endovascular repair of infrarenal abdominal aortic aneurysms. The EVAS FORWARD-IDE clinical trial is approved to enroll 180 patients at up to 30 centers in the U.S., Canada and Europe, of which approximately 25 will be in the U.S. The first procedure was performed by Professor Dittmar Boeckler, MD, a vascular surgeon at Heidelberg University Hospital in Germany. Healthcare Conference Schedules and Additional Loans - Research Report on Clovis Oncology, LifePoint, Halozyme, Infinity, and Endologix
PR Newswire - Thu Jan 09, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Clovis Oncology, Inc. (NASDAQ: CLVS), LifePoint Hospitals, Inc. (NASDAQ: LPNT), Halozyme Therapeutics, Inc. (NASDAQ: HALO), Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), and Endologix, Inc. (NASDAQ: ELGX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Endologix to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Mon Jan 06, 8:00AM CST
Endologix, Inc. (Nasdaq:ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that John McDermott, President and Chief Executive Officer, is scheduled to present at the 32 Annual JP Morgan Healthcare Conference in San Francisco, CA.
